TY - JOUR
T1 - ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology
AU - van Velthuysen, Marie-Louise F.
AU - Couvelard, Anne
AU - Rindi, Guido
AU - Fazio, Nicola
AU - Hörsch, Dieter
AU - Nieveen van Dijkum, Els J.
AU - Klöppel, G. nter
AU - Perren, Aurel
N1 - Funding Information: Marie‐Louise van Velthuysen, Anne Couvelard, Els J. Nieveen van Dijkum, Günter Klöppel and Aurel Perrenhave no conflicts of interest. Guido Rindi has received speakers fees from AAA and is consultant for Bracco. Nicola Fazio has received speakers fees from AAA, Hutchinson MediPharma, Merck and Novartis. Dieter Hörsch has received personalfees and grants from Lexicon Pharmaceuticals, Inc., Ipsen Pharmaceuticals, Inc., Novartis Pharmaceuticals, Inc., and Pfizer Pharmaceuticals, Inc., and advisory board honoraria from Advanz Pharma USA. Publisher Copyright: © 2022 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - In recent years the WHO classification of neuroendocrine neoplasms (NEN) has evolved. Nomenclature as well as thresholds for grading have changed leading to potential confusion and lack of comparability of tumour reports. Therefore, the European Neuroendocrine Tumour Society (ENETS) has set-up an interdisciplinary working group to develop templates for a pathology data set for standardised reporting of NEN. Experts of various disciplines, members of the ENETS Advisory Board, formed a taskforce that discussed and decided on the structure, content and the number of templates needed for reporting the most common NEN. The selection of the required items was based on the WHO classification of digestive system tumours, the WHO classification of tumours of the lung and mediastinum and on “ENETS standard of care” reports. The final proposal of the working group was approved by the ENETS Advisory Board. Templates for synoptic reporting were created for the seven most common NEN primary sites, that is, stomach, duodenum, jejunum-ileum, appendix, colon-rectum, pancreas, lung and mediastinum. In addition, a general template for reporting biopsies was designed. The templates allow the recording of the essential items on differentiation, proliferation (Ki-67 and mitosis), neuroendocrine features (positivity for chromogranin A and synaptophysin) and stage as well as several optional markers especially helpful for the distinction of neuroendocrine tumours (NET) from neuroendocrine carcinomas (NEC). In summary, this paper presents the content and development of synoptic reports for most sites of NEN by a multidisciplinary team of international experts in the field, which could help to improve unambiguous reporting of NEN.
AB - In recent years the WHO classification of neuroendocrine neoplasms (NEN) has evolved. Nomenclature as well as thresholds for grading have changed leading to potential confusion and lack of comparability of tumour reports. Therefore, the European Neuroendocrine Tumour Society (ENETS) has set-up an interdisciplinary working group to develop templates for a pathology data set for standardised reporting of NEN. Experts of various disciplines, members of the ENETS Advisory Board, formed a taskforce that discussed and decided on the structure, content and the number of templates needed for reporting the most common NEN. The selection of the required items was based on the WHO classification of digestive system tumours, the WHO classification of tumours of the lung and mediastinum and on “ENETS standard of care” reports. The final proposal of the working group was approved by the ENETS Advisory Board. Templates for synoptic reporting were created for the seven most common NEN primary sites, that is, stomach, duodenum, jejunum-ileum, appendix, colon-rectum, pancreas, lung and mediastinum. In addition, a general template for reporting biopsies was designed. The templates allow the recording of the essential items on differentiation, proliferation (Ki-67 and mitosis), neuroendocrine features (positivity for chromogranin A and synaptophysin) and stage as well as several optional markers especially helpful for the distinction of neuroendocrine tumours (NET) from neuroendocrine carcinomas (NEC). In summary, this paper presents the content and development of synoptic reports for most sites of NEN by a multidisciplinary team of international experts in the field, which could help to improve unambiguous reporting of NEN.
KW - NEC
KW - NET
KW - neuro endocrine neoplasm
KW - pathology report
KW - synoptic report
UR - http://www.scopus.com/inward/record.url?scp=85124586844&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/jne.13100
DO - https://doi.org/10.1111/jne.13100
M3 - Article
C2 - 35165954
SN - 0953-8194
VL - 34
JO - Journal of neuroendocrinology
JF - Journal of neuroendocrinology
IS - 3
M1 - e13100
ER -